MAP2K7 and thyroid gland carcinoma: The second study describes four BRAFV600E-mutated thyroid cancer patients with disease progression during BRAF or BRAF/MEK inhibitor treatment and acquisition of secondary mutations in RAS genes (KRASG12V in two patients, and NRASQ61K and NRASG13D in the others) [42].